A+ | A | A- | Skip to main content |

800 years stamp

Sensex

Nifty

USDINR

GBPINR

EURINR

BSE
NSE

Thursday, 16 July 2026 12:00 AM EOD	Asian-Paints2676.65	Hind-Unilever2098.55	ITC279.35	Trent2859.55	Larsen-and-Toubro3775.75	M-and-M3120.45	Reliance-Industries1293.00	Tata-Steel185.50	Titan-Company4625.30	SBI1031.35	Bharat-Electron407.05	Kotak-Mah-Bank377.15	Infosys1081.05	Bajaj-Finance1037.55	Sun-PharmaInds1950.00	HDFC-Bank808.30	TCS2201.80	ICICI-Bank1418.20	Power-Grid-Corpn280.80	Maruti-Suzuki13791.85	Axis-Bank1304.70	HCL-Technologies1188.05	NTPC342.50	Bharti-Airtel1921.85	Tech-Mahindra1511.35	Adani-Ports1825.70	UltraTech-Cem11779.85	Bajaj-Finserv1838.25	Interglobe-Aviat5266.90	Eternal286.45
15 mins delay SENSEX 77,186.87 [1.44]	6.80 0.25%	-3.80 -0.18%	2.90 1.05%	-8.20 -0.29%	-8.15 -0.22%	36.95 1.20%	-2.40 -0.19%	0.25 0.13%	48.00 1.05%	1.30 0.13%	-4.10 -1.00%	-1.25 -0.33%	4.65 0.43%	16.05 1.57%	-2.45 -0.13%	-7.05 -0.86%	12.90 0.59%	2.35 0.17%	0.10 0.04%	211.75 1.56%	-8.00 -0.61%	20.25 1.73%	-1.85 -0.54%	4.40 0.23%	12.70 0.85%	-3.80 -0.21%	-30.50 -0.26%	-11.85 -0.64%	95.35 1.84%	-8.30 -2.82%

Hot Pursuit

Scrips, which has significant changes during the market hours.

AstraZeneca Pharma India gets CDSCO nod for additional Fasenra indication

16-Jul-26 15:25Hrs IST

The approval is for an additional indication of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra). The drug is now indicated for the treatment of patients aged 12 years and above with hypereosinophilic syndrome (HES) without an identifiable non-haematologic secondary cause.

The receipt of this permission paves the way for the marketing of Benralizumab 30 mg/ml solution for injection in a pre-filled syringe (brand name: Fasenra) in India for the specified additional indication, subject to receipt of related statutory approvals, if any.

AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

The company's standalone net profit declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025.

The counter slipped 1.77% to Rs 8,092 on the BSE.

Powered by Capital Market - Live News

Attention Investor :

"Prevent unauthorised transactions in your account ; Update your mobile numbers/email IDs with Us. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day” - Issued in the interest of Investors"

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"No need to issue cheques by investors while subscribing to Equity IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

"Contents which are exclusively for Non-Broking Products/Services, "Mutual Fund, Mutual Fund-SIP, Research reports, Insurance, etc. where the Member is just a distributor. These are not Exchange traded product and the Member is just acting as distributor. It should also state that all disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism."

A Muthoot M George Enterprise